LRRK2 inhibitors
US11993612B2 · kind B2 · utility
0Cited by
1References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 8, 2023 |
| Grant date | May 28, 2024 |
| Priority date | — |
| Expiry date | Jun 8, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention is directed to compounds of formula IThe compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.